How to Verify PT-141 (Bremelanotide) Purity and Batch Documentation

PT-141, formally bremelanotide (also written BMT or BRM), is a synthetic cyclic heptapeptide and a macrocyclic peptide melanocortin receptor (MCR) agonist. It is the active moiety of bremelanotide acetate, the salt form in which the peptide is commonly supplied, and it is structurally derived from the MT-II scaffold; its sequence incorporates a lactam bridge that constrains the ring and a D-amino acid residue, features associated with resistance to proteolytic degradation and enhanced conformational rigidity in peptide drug design [11]. The compound is a macrocyclic peptide of the class that includes setmelanotide, and it has been described as balancing small-molecule and biologic properties in terms of affinity, stability and pharmacokinetics [1]. The work on this molecule centres on the melanocortin receptor family, with MC4R activation the mechanism most directly implicated in the central pathways studied in hypoactive sexual desire disorder (HSDD) [8].

Verification of a research batch therefore rests on three separable questions: is the material the correct peptide (identity), how much non-peptide material is present (purity), and what does the accompanying documentation actually attest to (batch records, method summaries, certificates of analysis). Because bremelanotide is a cyclic peptide with a defined degradation profile, identity and purity cannot be inferred from a single chromatographic peak; the published characterisation work on bremelanotide acetate and its degradants used LC-HRMS/MS alongside computational modelling to assign degradation products, including epimerisation pathways [9]. That study is the most directly relevant analytical reference for anyone assessing a batch, and it is discussed below alongside the receptor pharmacology and clinical-trial context that define what the material is used to study.

Research Studies

Bremelanotide and melanocortin receptor selectivity across MC1R, MC3R, MC4R and MC5R

Bremelanotide belongs to the macrocyclic peptide class whose selectivity across the human melanocortin receptors has been mapped in structure-activity work. A series of 14 macrocyclic peptide analogues (19–23-membered rings) built on the MT-II, SHU-9119 and PG-901 scaffolds was synthesised and assessed pharmacologically against human MC1R, MC3R, MC4R and MC5R [1]. The framing of that work is that macrocyclic peptides such as bremelanotide and setmelanotide have shown clinical success while still presenting a challenge in achieving selective MCR targeting with optimal pharmacological profiles [1]. For batch verification, the practical implication is that receptor-selectivity data are a property of the defined peptide sequence and ring size, so an identity claim should be tied to a sequence-level characterisation rather than to a binding result alone.

Bremelanotide and MC4R activation in HSDD neuroimaging

The receptor mechanism most often attached to bremelanotide in the clinical literature is MC4R activation. A randomised, double-blind, placebo-controlled, two-way crossover physiological study was designed to evaluate the effects of MC4R activation on brain activity patterns and behavioural psychometric measures of sexual arousal during visual erotic stimuli in approximately 40 right-handed, heterosexual, premenopausal women aged 18 years and over with HSDD of at least six months' duration [8]. This is a mechanistic study design rather than a purity study, but it establishes the receptor target against which batch activity would be interpreted in a research setting.

Bremelanotide and efficacy endpoints in premenopausal HSDD

A Phase 3, bridging, multicentre, randomised, double-blind, placebo-controlled, parallel-group trial was designed to evaluate the efficacy and safety of subcutaneously administered bremelanotide in premenopausal women with HSDD, with or without decreased arousal [7]. A separate systematic review of completed studies registered on ClinicalTrials.gov examined emerging pharmacological therapies for HSDD in adult women, noting that pharmacological options remain limited and that evidence from individual trials is heterogeneous [2]. Neither source provides purity specifications; they are cited here because they define the clinical populations and endpoints in which bremelanotide has been studied.

Bremelanotide and pharmacokinetics in lactating women

An open-label pharmacokinetic study was designed to evaluate whether bremelanotide is secreted in breast milk and to measure its concentration and characterise its pharmacokinetics in lactating women given a single 1.75 mg subcutaneous dose, in 10 healthy lactating female subjects between 10 days and 6 months post-partum [4]. The relevance to documentation is indirect but real: pharmacokinetic work of this kind depends on a characterised, quantified dose, which is why batch-level identity and purity records matter for any study that reports concentrations.

Bremelanotide and co-administration with tirzepatide in obesity

A prospective, randomised, double-blind, placebo-controlled study was designed to assess the safety and efficacy of bremelanotide used in combination with tirzepatide therapy in the treatment of obesity in subjects with a BMI from 30.0 to 45.0 kg/m² inclusive [5]. This is a combination-therapy design, and it illustrates that bremelanotide appears in research contexts well outside the sexual-medicine indication.

Bremelanotide and diabetic kidney disease histopathology

A Phase IIb, multicentre, open-label, prospective study was designed to assess the efficacy of the melanocortin receptor agonist bremelanotide when administered with RAAS inhibition therapy after six months in subjects with Type II diabetic nephropathy; all subjects were to remain in the trial for further assessment and undergo a diagnostic renal biopsy at 12 months to assess the effect of melanocortin therapy on diabetic histopathology [6]. Again, the endpoint is tissue-level, and the study is cited to show the breadth of the melanocortin research programme rather than to support any purity claim.

Bremelanotide acetate and its degradants by LC-HRMS/MS

The most directly applicable analytical reference is a study that developed a stability-indicating RP-HPLC method for bremelanotide and characterised its degradation products using LC-HRMS/MS combined with computational approaches, including prediction of epimerisation through modelling [9]. The study's stated premise is that the intrinsic stability and degradation behaviour of this cyclic peptide therapeutic had not been extensively investigated [9]. For batch verification, this is the reference that defines what a purity method should be able to resolve: the parent peptide separated from its degradation products, with mass-spectrometric assignment of those products.

Bremelanotide and the D-amino acid design rationale

Bremelanotide contains a D-amino acid residue, and the rationale for that feature is set out in the wider literature on FDA-approved drugs containing D-amino acids: the non-natural enantiomers of L-amino acids confer resistance to proteolytic degradation, enhanced conformational rigidity and reduced immunogenicity, making them valuable in long-acting peptide design [11]. This matters for verification because epimerisation is a documented degradation route for bremelanotide [9]; a batch record that does not address stereochemical integrity is incomplete for a peptide whose design depends on a defined stereochemistry.

Bremelanotide and peptide therapeutics in aging research

Bremelanotide appears within the broader review literature on therapeutic peptides in gerontology, which covers mechanisms, clinical applications, evidence base and safety profiles of peptides with demonstrated or potential applications in healthy aging and age-related conditions, targeting hallmarks including metabolic dysfunction, telomere attrition, tissue repair impairment and hormonal decline [3]. This is context, not a purity specification, and it is included only to indicate where melanocortin peptides sit in the wider peptide-therapeutics landscape.

Comparison of documentation elements to verify

If you are reading this for personal health reasons

This material is sold for laboratory research only, and nothing on this page is medical or dosing guidance. We do not provide dosing information or clinical advice for any compound. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

• [1] Goldilocks-Inspired Design of Mid-Size Macrocycles for Selective Targeting of Human Melanocortin Receptors — https://europepmc.org/article/PMC/PMC13492293
• [2] Clinical trial evidence on emerging pharmacological therapies for hypoactive sexual desire disorder in women — https://europepmc.org/article/PMC/PMC13237691
• [3] Therapeutic peptides in gerontology: mechanisms and applications for healthy aging — https://europepmc.org/article/PMC/PMC13095733
• [4] Single Dose of Vyleesi in Lactating Female Subjects to Measure the Concentration of Bremelanotide in Breast Milk — https://clinicaltrials.gov/study/NCT06867835
• [5] A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity — https://clinicaltrials.gov/study/NCT06565611
• [6] A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney Disease — https://clinicaltrials.gov/study/NCT05709444
• [7] A Phase 3, Bridging, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder — https://clinicaltrials.gov/study/NCT04943068
• [8] Role of the Melanocortin-4 Receptor in Hypoactive Sexual Desire Disorder — https://clinicaltrials.gov/study/NCT04179734
• [9] Comprehensive characterization of bremelanotide acetate and its degradants by LC-HRMS/MS and predicting epimerization through computational modelling — https://pubmed.ncbi.nlm.nih.gov/42485063/
• [10] Quantification of "Mercy Sex" in Heterosexual Women — https://pubmed.ncbi.nlm.nih.gov/42144994/
• [11] FDA-Approved Drugs Containing D-Amino Acids: A Historical and Developmental Perspective — https://pubmed.ncbi.nlm.nih.gov/42041173/
• [12] Should Bremelanotide Be Considered for the Treatment of Sexual Arousal and Desire Disorders in Men? — https://pubmed.ncbi.nlm.nih.gov/41960633/